[Use of aminoglutethimide in the hormonal treatment of patients with advanced breast cancer].
54 patients (pts) with metastatic breast cancer were treated with aminoglutethimide 250 mg p.o. twice a day with hydrocortisone 40 mg p.o./day. All pts were postmenopausal, mean age 63 years, and pretreated with cytostatics and/or hormones. Dominant sites of metastases were: soft tissues 29 pts. bone 12 pts. lungs 6 pts. Objective responses were: 4 (7.4%) CR, 15 (27.8%) PR, 16 (29.6%) NC and 19 (35.2%) PD (UICC criteria). The response (CR + PR) at metastatic sites was: soft tissues 12 (41%), bone 4 (33%). The mean response duration was 15.0 months for CR; 10.2 for PR and 5.5 months for NC. The results of the study confirm that low--dose aminoglutethimide is an effective second-line hormonal treatment of advanced breast cancer.
Wojtacki
J
J
Kliniki Chirurgii Onkologicznej AM w Gdańsku.
Dziewulska-Bokiniec
A
A
Czech
I
I
D000368:Aged; D000369:Aged, 80 and over; D000616:Aminoglutethimide / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000556:secondary; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000008:administration & dosage; D008175:Lung Neoplasms / Q000556:secondary; D008875:Middle Aged; D012983:Soft Tissue Neoplasms / Q000556:secondary; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D000616:Aminoglutethimide; D006854:Hydrocortisone
Zastosowanie aminoglutetymidu w hormonoterapii chorych z zaawansowanym rakiem sutka.